Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.

Excellence is just the beginning.


French German Italian Portuguese Russian

Drug Treatment Study for Recurrent or Progressive Glioblastoma

Clinical Trial Title: 
A study of DSP-7888 dosing emulsion in combination with bevacizumab in patients with recurrent or progressive glioblastoma following initial therapy.
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
Clement Pillainayagam, MD
Clinical Trial Protocol Description: 

The main purpose of this phase II study is to compare the effectiveness of treatment with DSP 7888 in combination with bevacizumab versus bevacizumab alone in patients with glioblastoma (GBM). Bevacizumab has been approved by the U.S. Food and Drug Administration (FDA) to treat GBM. DSP-7888 is not approved for use by the FDA, although it has allowed the drug to be tested in studies such as this one.

Another purpose of this study is to learn more about a newly discovered experimental vaccine drug, DSP-7888 Dosing Emulsion (or simply DSP-7888), that is being tested in people with your type of cancer. This drug may help the immune system to fight against cancer cells that have a protein called WT1 (Wilms’ Tumor 1 gene). It is hoped that with the administration of DSP-7888 the immune system may be able to kill or slow down the growth of cancer cells.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have a diagnosis of glioblastoma.
  • Have evidence of recurrence or progression of disease.
  • Have recovered from effects of all prior therapies.

You will be excluded from the study if any of the following criteria apply to you:

  • Have received prior Bevacizumab therapy.
  • Have received anti-neoplastic therapy, including RT, for first relapse or recurrence.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Brain Tumors
Contact Phone: 
(312) 942-8729
Contact Name: 
Praneeth Chebrolu, MBBS, MS